Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Dabrafenib in BRAF V600-Mutant Non-small Cell Lung Cancer
KCT0003021Phase 2Recruiting
- Sponsor
- Asan Medical Center
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib and dabrafenib + trametinib in non-small cell lung cancer (NSCLC), sponsored by Asan Medical Center. Started May 2018; status: recruiting.
02
Drugs
trametinibdabrafenib + trametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0003021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003021.